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The vasculature is essential for proper organ
function. Many pathologies are directly and indi-
rectly related to vascular dysfunction, which
causes significant morbidity and mortality. A com-
mon pathophysiological feature of diseased vessels
is extracellular matrix (ECM) remodelling. Analys-
ing the protein composition of the ECM by conven-
tional antibody-based techniques is challenging;
alternative splicing or post-translational modifica-
tions, such as glycosylation, can mask epitopes
required for antibody recognition. By contrast,
proteomic analysis by mass spectrometry enables
the study of proteins without the constraints of
antibodies. Recent advances in proteomic tech-
niques make it feasible to characterize the compo-
sition of the vascular ECM and its remodelling in
disease. These developments may lead to the
discovery of novel prognostic and diagnostic mark-
ers. Thus, proteomics holds potential for identify-
ing ECM signatures to monitor vascular disease
processes. Furthermore, a better understanding of
the ECM remodelling processes in the vasculature
might make ECM-associated proteins more attrac-
tive targets for drug discovery efforts. In this
review, we will summarize the role of the ECM in
the vasculature. Then, we will describe the chal-
lenges associated with studying the intricate net-
work of ECM proteins and the current proteomic
strategies to analyse the vascular ECM in meta-
bolic and cardiovascular diseases.
Keywords: apolipoproteins, atherosclerosis, diabetes,
proteomics, restenosis, vascular biology.
Introduction
Vascular smooth muscle cells (VSMCs) synthesize
and maintain a complex meshwork of extracellu-
lar matrix (ECM) [1]. Constituting around 300
proteins, the ECM is an intricate three-dimen-
sional, noncellular lattice composed of elastin,
collagen, proteoglycans (PGs) and glycoproteins
[2]. The function of the ECM goes beyond provid-
ing a supporting framework for the cellular con-
stituents. The ECM is increasingly being
recognized as a dynamic structure with multi-
faceted functions. In addition to providing phys-
ical support for tissue integrity and elasticity, the
ECM serves as a reservoir for bioactive molecules,
including growth factors, cytokines and proteases,
that are required for tissue homeostasis [3]. The
importance of the ECM is demonstrated by the
substantial number of pathologies related to ECM
abnormalities [4]. Of more relevance, ECM dys-
regulation has been implicated in diseases affect-
ing the vasculature. These include but are not
limited to aneurysms [5], vein graft failure [6],
varicose veins [7], diabetic vasculopathy [8],
restenosis and atherosclerosis [9].
The ECM of the vasculature
The vascular ECM can be divided into two lower-
order structures: the basement membrane (BM)
and the interstitial matrix.
The BM is a specialized ECM protein complex
separating the endothelium from the underlying
connective tissue [10]. The close proximity to the
cells provides mechanical stability and controls cell
organization and polarity. Some of the main pro-
tein components of the BM include laminins;
collagens IV, XV and XVIII; perlecan; agrin; and
nidogen [11]. Perlecan is a particularly large PG
(469 kDa) and is essential for the stability of the
BM. It has domains for interaction with other
components of the BM such as collagen IV and
laminins [12]. The N-terminal domain contains the
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majority of anchoring sites for heparan sulphate
PGs, which combined with their position in the
BM enable perlecan to participate in signalling
events [12]. It is interesting that endorepellin, an N-
terminal peptide from perlecan released by
proteolytic action, has important anti-angiogenic
properties [13].
The interstitial matrix determines most of the
mechanical properties of the tissue [14]. Although
anchored to the BM, it forms a distinct functional
unit that provides the means (via an extracellular
compartment) through which signals are dis-
tributed and nutrients and fibroblasts migrate
[15]. The main components of the interstitial
matrix in the vessel wall are elastin, collagens I,
III, VI and XII and PGs [16].
Collagen
Collagens are a large family of proteins with triple
helix conformations and are present in many
tissues. Structurally, the collagens contain three
alpha polypeptide chains that form a right-
handed coil with hydrogen bonds linking adjacent
chains [17]. Heterotrimeric forms in the vascula-
ture include collagens I, IV, V and VI, whilst the
homotrimeric structure (with three identical
chains) includes for example collagens III, XVIII
and XV. The extensive number of collagen sub-
types gives rise to an equally extensive variety of
functions, ranging from the structural support of
tissues to cell adhesion and migration, angiogen-
esis and tissue repair. The fibrillar forms of
collagen are the main tensile element in many
tissues. In the vasculature, fibrillar collagens are
mainly represented by types I, III and V [18]. By
contrast, other collagen types form networks (i.e.
collagens IV and VIII), which are key components
of the BM. Additional forms of collagen are
important for cell adhesion and organization (i.e.
collagens VI and XIV) and anchoring of other
components within the ECM (i.e. collagen VII).
Furthermore, some collagens have been found to
contain domains that exert regulatory roles when
released by proteolytic activity. This includes, for
example, endostatin, a C-terminal fragment of
collagen XVIII. Additionally, new forms of colla-
gens have been identified with transmembrane
domains, further adding to the ubiquity and
multifunctionality of this family of proteins. The
detailed classification of collagens has been
extensively reviewed elsewhere [19].
Elastin
Elastin is the principal component of elastin
lamellae, the fenestrated layers present in the
tunica media of arteries. Similar to fibrillar colla-
gens, the functional form of elastin is a cross-
linked amalgamate of tropoelastins, that is the
elastin gene product. Elastic recoil imparted by
elastic fibres is an essential property for normal
cardiovascular function [16]. Briefly, large elastic
arteries allow blood pressure to be maintained
throughout the cardiac cycle by storing a portion of
the stroke volume with each systole. Subsequently,
discharging that volume with diastole reduces the
left ventricular afterload [20]. This phenomenon is
known as the ‘Windkessel’ effect. Less compliant
elastic arteries result in a diminution of the Wind-
kessel effect with age and lead to hypertension,
predisposing to conditions such as myocardial
infarction, stroke and heart failure.
Glycoproteins
Glycosylation, the covalent attachment of carbo-
hydrate molecules to a core protein, is a common
post-translational modification (PTM) of ECM pro-
teins. There are two types of glycoproteins: N-
glycosylated glycoproteins, in which the sugar is
attached to the amide nitrogen of asparagine, and
O-glycosylated glycoproteins, in which the sugar is
attached to an oxygen atom of hydroxylysine,
hydroxyproline (Hyp), serine or threonine [21].
Due to the presence of specialized domains and
carbohydrate residues, glycoproteins are essential
components for cell adhesion and for mediating
attachment of cells to the BM [21]. Laminins and
fibronectin are the two most important examples of
this class of glycoprotein.
Proteoglycans
Originally identified as major components of carti-
lage, PGs were for years thought to be specific for
cartilage [22]. However, they have since been found
in virtually all tissues, where they are distributed
within the interstitial matrix and BM. PGs have a
basic structure comprising a core protein and a
variable number of glycosaminoglycan (GAG)
chains usually attached through O-glycosidic link-
ages to serine residues in the core protein. One
classification system of PGs is based on the type of
attached GAGs: (i) chondroitin sulphate and der-
matan sulphate, consisting of repeating disaccha-
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ride units of galactosamine and either glucuronic
acid or iduronic acid, (ii) heparan sulphate, con-
sisting of repeating disaccharide units of glu-
cosamine and either glucuronic acid or iduronic
acid, and (iii) keratan sulphate, consisting of
repeating disaccharide units of glucosamine and
galactose [23].
Within the vessel wall, the two most abundant PGs
are large aggregating PGs and small leucine-rich
PGs (SLRPs).
Versican is an important large aggregating PG in
the vessel wall, not least due to its involvement in
the retention of lipoproteins and development of
atherosclerosis (reviewed by Wight and Merrilees
[24]). Versican has also been implicated in smooth
muscle cell proliferation and migration contribut-
ing to restenosis [25]. As a chondroitin sulphate
PG, versican is secreted with a structure consisting
of a large globular domain at each end and an
intermediate domain carrying chondroitin sul-
phate chains. Through its globular domains, ver-
sican interacts with hyaluronic acid. Versican has
high homology at the globular domains to other
PGs that bind hyaluronic acid (‘hyalecticans’ such
as aggrecan, brevican and neurican), but the
intermediate region varies considerably in terms
of sequence, length and number of chondroitin
sulphate chains. Splice variants, truncated glyco-
forms and stable degradation products further
increase the diversity of this PG family [26].
Small leucine-rich PGs are a family of biologically
active ECM components belonging to the leucine-
rich repeat superfamily of proteins [27]. Their
dominant feature is the presence of leucine-rich
repeats flanked by cysteine clusters in the core
protein. After their synthesis, SLRPs are secreted
into the pericellular space where they interact with
different extracellular molecules and the plasma
membrane, modulating a variety of processes
including collagen fibrillogenesis and TGFb
sequestration [28, 29]. Prominent vascular SLRPs
include decorin, biglycan and lumican [30]. Stud-
ies in knockout mice have shown some degree of
functional overlap between different SLRPs [31].
There are several families of PGs in which the
protein core is partly integrated into the plasma
membrane, with their GAG-containing regions
exposed on the extracellular side of the membrane.
These PGs are important for anchoring and sig-
nalling between cells and the ECM. Syndecans and
dystroglycans are part of this group and mediate
cell–matrix interactions.
PTMs of the ECM
Extracellular matrix proteins are known to
undergo extensive PTMs such as hydroxylation
and glycosylation.
Hydroxylation
As mentioned above, all collagens form triple
helices and this characteristic increases molecular
stability and provides resistance to tensile stress,
which is particularly important for fibril-forming
collagens. Different forms of collagen exist in the
vasculature, but in general, a common pattern can
be observed for amino acid sequences of every type
of collagen; each chain has enriched triplet repeats,
starting with a glycine residue followed by proline
and Hyp. The presence of this repetitive sequence
is key for the constitution of the right-handed helix,
and Hyps provide the substrate for the formation of
hydrogen bonds between the adjacent alpha
chains. Moreover, this putative triplet is modified
in different forms of collagen, resulting in multiple
permutations that are responsible for the func-
tional and spatial diversity of the collagen family
[32]. During collagen synthesis, Hyp is derived
from proline oxidation and the modification is
introduced at specific positions once the protein
has been synthesized. Then, collagens are secreted
into the extracellular space. Prolyl-4-hydroxylase
and prolyl-3-hydroxylase catalyse the hydroxyla-
tion of specific proline residues in the lumen of the
endoplasmic reticulum. The former enzyme reacts
on proline within a motif of X-Pro-Gly (where X is
any amino acid), and the latter appears to require a
Pro-4-Hyp-Gly sequence [33, 34].
Glycosylation
Glycosylation is important for correct folding
and stability whilst also contributing to the
biological functions of glycoproteins [21]. ECM
proteins tend to be extensively modified by
addition of N- and O-linked large, repetitive
GAGs and shorter and diverse N- and O-linked
oligosaccharides. N-linked glycosylation occurs at
asparagine within a consensus sequence of
Asn-X-Ser/Thr (N-X-S/T), where X can be any
amino acid except proline [35]. UniProtKB con-
tains 15,828 sites for the human proteome,
where the N-X-S/T sequon is annotated as the
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N-glycosylation site. It has been suggested that
only 27% of all N-X-S/T sequons are glycosylated
[36], highlighting the importance of studying
glycosylation to better understand the properties
of the ECM. Unlike N-glycosylation, there is no
consensus sequence for O-linked glycosylation,
which occurs on the amino acids serine and
threonine.
Degradation of the vascular ECM
All vascular cells have the ability to remodel their
surrounding ECM. The ECM is subject to the
action of proteolytic enzymes, which maintain a
dynamic equilibrium between protein synthesis
and degradation. Amongst these, enzymes are the
members of a disintegrin and metalloproteinase
(ADAM) and a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTS) families,
serine proteases (e.g. plasmin, neutrophil-derived
elastase and cathepsin G), cysteine proteases
(cathepsins B, L and S), aspartyl proteases (cathep-
sin D) and matrix metalloproteinases (MMPs).
Matrix metalloproteinases
Matrix metalloproteinases are a family of 23 pro-
teases that use zinc as a cofactor. In general, they
are synthesized as inactive pro-MMPs in which the
catalytic domain remains inaccessible due to the
interaction of the N-terminal propeptide with Zn2+.
Once the propeptide is released by proteolytic
action, the catalytic domain is exposed and the
enzyme becomes active. After being secreted, pro-
MMPs bind to different molecules of the ECM and
lie dormant, forming a reservoir that can be acti-
vated immediately upon demand [37]. Due to the
effectiveness of these enzymes, establishing strict
control of their activity is essential. The tissue
inhibitors of matrix metalloproteinases (TIMPs) are
low molecular weight proteins that bind avidly to
MMPs, inhibiting their activity [38]. TIMP-1, TIMP-
2 and TIMP-3 collectively inhibit all metalloprotei-
nases with different substrate specificity [1]. MMP
and TIMP activities with respect to cardiovascular
disease (CVD) have attracted most attention so far,
and although inhibitory antibodies of MMPs have
shown effects in animal models, there is significant
disparity when tested in patients [15].
ADAMs and ADAMTSs
The ADAMs family, which is related to the MMPs,
can be categorized as either membrane-anchored
ADAMs or as secreted ADAMTSs [39]. Given their
greater propensity to interact with the ECM, we will
primarily focus on the ADAMTS family.
The ADAMTSs are synthesized as inactive pre/pro-
enzymes and contain, like MMPs, a metalloprotei-
nases catalytic domain. The enzyme furin has been
implicated in pro-protein processing and subse-
quent activation. However, other enzymes may be
involved and there is evidence to suggest that
ADAMTS-7 [40] and ADAMTS-13 [41] are catalyt-
ically active with their pro-domain attached. The
major ECM-related functions of the ADAMTS
family appear to be the cleavage of the large
aggregating PGs (aggrecan and versican) as well
as the processing of pro-collagen to collagen via
removal of the N-terminal pro-peptides [42].
Seminal work by Jonsson-Rylander et al. [43]
indicated a role for ADAMTS-1 in atherosclerosis.
The authors hypothesized that the cleavage of ECM
proteins may facilitate VSMC migration based on
the increased ADAMTS-1 expression observed in
atherosclerotic plaques. Our group highlighted the
importance of ADAMTS-5 in a mouse model of
atherosclerosis [44]: lower levels of ADAMTS-5
accompanied accumulation of versican in aortas
of apolipoprotein (apo)E-knockout mice. Versican
cleavage was barely detectable in aortas from
ADAMTS-5-deficient mice providing conclusive evi-
dence that in mice, ADAMTS-5 is the key enzyme
for versican degradation in the vasculature.
Proteomic studies of the vascular ECM
A comprehensive characterization of the ECM is
essential for the understanding of vascular disease
processes. Initially, the vascular ECM was mainly
studied by antibody staining or by mRNA analysis.
For example, Kirsch et al. [45] compared protein
expression between human varicose and normal
veins with antibodies against collagen IV, laminin,
fibronectin and tenascin. Although the authors
found significant differences between the diseased
andhealthyspecimens, thestudywas limited toonly
a few ECM proteins. In cardiovascular research,
proteomic studies predominantly investigate
cellular proteins; thus, the extracellular space
remains relatively underexplored. Even the ECM
compositionofdifferentvascular territories is largely
unknown. The detection of ECM proteins by pro-
teomics was initially limited by problems in extract-
ing insoluble ECMproteins and contamination from
more abundant cytosolic and mitochondrial pro-
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teins. Since then, we and others have employed a
stepwiseextractionofECMproteinsthat isamenable
to analysis by liquid chromatography–tandemmass
spectrometry (LC-MS/MS) [18] (Fig. 1).
Proteomics for the analysis of ECM composition
In one of a few studies that targeted the ECM,
Talusan et al. [46] performed proteomic analysis on
human pre-atherosclerotic lesions from the carotid
artery after PG extraction. Using internal thoracic
arteries for a comparative control, they observed
increased levels of lumican in the atherosclerotic-
prone carotid arteries. In the 10 years since this
important work, no comprehensive proteomic anal-
ysis of the ECM has been performed in atheroscle-
rosis. This is surprising, especially given the recent
technological and methodological developments.
Similar approaches have been utilized effectively
in characterizing the composition of the ECMs of
other normal and diseased tissues [47]; in addition
to our studies of the ECM signatures in abdominal
aortic aneurysm [48] and aorta [18], Hansen and
colleagues showed differential expression of a
number of ECM proteins in the internal thoracic
artery associated with arterial stiffness, as
assessed by pulse wave velocity [49]. The same
group also found that levels of BM proteins were
elevated in internal thoracic arteries of patients
with type 2 diabetes mellitus [50].
There are few analogous studies, illustrating a
significant void in the current literature (Table 1).
Proteomics for the analysis of PTMs of the vascular ECM
As discussed above, two PTMs are key for the
analysis of the ECM: hydroxylation and glycosyla-
tion. The inclusion of hydroxylation of proline (i.e. a
proline 16 Da heavier due to addition of OH) in
search parameters improves the detection of colla-
gens (Fig. 2). Figure 3 shows the effect on selected
ECM proteins (biglycan, mimecan and galectin-1)
of treating tissue extracts either with enzymes for
GAG removal alone or a combination with five
additional enzymes for the removal of complex
oligosaccharides. Biglycan contains small oligosac-
charide residues as well as larger GAGs. Few ECM
proteins (e.g. galectin-1) are devoid of glycosyla-
tions.
Proteomics for the analysis of ECM degradation
As mentioned above, another important factor in
ECM vessel wall remodelling is the role of MMPs.
The earliest studies linking MMPs to vascular
remodelling concerned intimal thickening following
balloon angioplasty and vein grafting [51]. Indeed,
knockout studies in mice showed that MMP-2,
MMP-9 and MMP-14 were essential for neointimal
hyperplasia. Consistent with these findings, TIMP
gene transfer was also shown to hinder intima
thickening in animal models of vascular balloon
Human tissue
Animal models
Cell culture
0.5 M NaCl
0.08% SDS
4 M GuHCl
Proteases
Growth factors
New synthesis
Intracellular and 
membrane 
proteins
ECM integral 
proteins
Proteins 
Peptides
DIGESTION 
BEFORE SDS
AFTER SDS
Fig. 1 Proteomics workflow targeting the extracellular
matrix (ECM). Biochemical subfractionation allows enrich-
ment of ECM proteins. Vascular tissues of human origin or
those obtained from animal models of cardiovascular
disease are initially incubated in 0.5 mol L1 NaCl to
extract proteases, growth factors and newly synthesized
ECM proteins. A subsequent decellularization step is
performed with a buffer containing sodium dodecyl sul-
phate (SDS) before integral, polymeric ECM proteins are
extracted with guanidine hydrochloride (GuHCl). Proteins
obtained after sequential extraction are digested into
peptides before liquid chromatography–tandem mass
spectrometry analysis. The histological panel (haema-
toxylin and eosin staining) demonstrates the efficacy of
SDS in removing cellular components before extraction of
ECM proteins in human aortas. L, lumen; I, intima; M,
media. Adapted from Didangelos et al. [18].
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injury [52]. However, despite showing promising
signs as a potential therapeutic target, efforts to
inhibit MMP activity using synthetic MMP inhibi-
tors have yet to provide clinical benefits [53].
Seminal research by Henney et al. [54] implicated
MMP-3 in the human atherosclerotic plaque,
leading a paradigm shift away from the concept
that the atheroma is an inert obstruction. Since
then, a spectrum of MMPs and TIMPs has been
shown to be responsible for plaque destabilization
including collagenases MMP-1, MMP-2 and MMP-3
and TIMP-1 and TIMP-2. Much of our understand-
ing of the role of MMPs in vascular diseases has
come from transgenic or knockout mice with sub-
sequent transcript and histological analysis; how-
ever, the results are often conflicting and
confounding. For example, Luttun et al. [55]
reported that MMP-9-null mice exhibited more
stable plaques, compared to wild-type animals as
a result of a reduction in plaque size, macrophage
content, collagen deposition and elastin degrada-
tion, whereas Johnson et al. [56] suggested that
MMP-9 was protective as the knockout model
exhibited compositional changes associated with
plaque instability.
We used proteomics to search for proteolytic frag-
ments that were upregulated during ECM remod-
elling in abdominal aortic aneurysms [48]. Using
human samples, we showed that the degradation
of six glycoproteins was linked to MMP-12 activity.
Similarly, we also used proteomics to identify
potential substrates of other MMPs (MMP-3,
MMP-9, MMP-14) in vascular tissues [57]. How-
ever, there is a need for more comprehensive
analysis of the ‘degradome’ to investigate beyond
the commonly studied MMPs.
Targeted proteomics
A limitation of contemporary LC-MS/MS is the bias
towards highly abundant proteins. With large
arteries and atherosclerotic vessels, this is exacer-
bated due to the higher cellular content and
inflammatory cell infiltration in disease. Whilst
enrichment steps have to a degree alleviated the
problem, bias still remains. In an untargeted
discovery proteomic experiment, the selection of
peptides for fragmentation is a stochastic process
leading to incompleteness of data and run-to-run
variability. Instead, a targeted proteomic strategy
can be employed that offers increased selectivity,
sensitivity and quantitative accuracy. The most
common targeted strategies are known as selected
reaction monitoring and multiple reaction moni-
toring [58, 59]. In essence, targeted proteomic
analyses only consider the peptides of interest, as
Table 1 Proteomics analysis after extracellular matrix (ECM) enrichment
Study/year Tissue/species Extraction method Findings
Didangelos et al. (2010) [18] Aorta (Human) 0.5 mol L1 NaCl (4 h)
0.08% SDS (4 h)
4 mol L1 GuHCl (48 h)
321 total proteins
84 extracellular proteins
Naba et al. (2012) [81] Lung (Mouse) Compartmental Protein
Extraction kit
184 total proteins
55 matrisome proteins
de Castro Bras et al. (2013) [90] Left ventricle (Mouse) 0.5 mol L1 NaCl (O/N)
1% SDS (3–5 days)
4 mol L1 GuHCl (48 h)
157 total proteins
17 ECM proteins
Brachvogel et al. (2013) [91] Cartilage (Mouse) 1 mol L1 NaCl (24 h)
4 mol L1 GuHCl (24 h)
397 total proteins
Barallobre-Barreiro et al. (2012) [92] Left ventricle (Pig) 0.5 mol L1 NaCl (4 h)
0.08% SDS (4 h)
4 mol L1 GuHCl (48 h)
139 extracellular proteins
Decaris et al. (2014) [93] Lung (Mouse) 0.5 mol L1 NaCl (2 h)
0.08% SDS (16 h)
4 mol L1 GuHCl (48 h)
N/A
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defined by the user. Thus, analysis time is not
wasted on other peptides from highly abundant or
contaminating proteins. Typically, targeted pro-
teomics is utilized as a means to validate discovery
proteomic data as the amino acid sequence infor-
mation of the protein of interest must be known
and the best peptides for targeted proteomic anal-
ysis should have already been identified. Targeted
proteomics provides a method to quantify low-
abundance proteolytic fragments or protein iso-
forms [60, 61]. This is particularly useful given that
antibodies are not always available for neoepitopes
generated after proteolytic cleavage of ECM pro-
teins [57]. Targeted proteomics is also applicable
for studying PTMs.
Glycoproteomics of the ECM
A common large-scale proteomic strategy for N-
glycopeptide analysis utilizes a glycopeptide
enrichment step followed by glycan removal. Typ-
ical methods to enrich glycosylated peptides
involve the use of one or more of the following:
lectins, hydrophilic interaction liquid chromatog-
raphy, hydrazide or graphite [62]. Subsequently,
PNGase-F is used to remove the glycan moiety,
serving two purposes: first, the core peptide can be
analysed without interference from sugars during
fragmentation; and secondly, via a deamidation
reaction, PNGase-F converts the asparagine to
aspartic acid. This conversion is characterized by
a mass shift of 0.984 Da. If the reaction is per-
formed in the presence of H2O
18 (water that con-
tains an isotopic form of oxygen: oxygen-18 instead
of oxygen-16), this leads to a mass shift of 2.98 Da
[63] and further improves confidence that the site
was glycosylated and the conversion did not occur
spontaneously. We have previously treated pro-
teins secreted by endothelial cells with PNGase-F
in the presence of O18-labelled water prior to LC-
MS/MS analysis [64]. More recently, we applied the
same method to more complex extracts from
human vascular tissues. Treatment with PNGase-
F in O18-labelled water allowed the identification of
peptides that contain glycosylated asparagines,
leading to improved sequence coverage for heavily
N-glycosylated ECM proteins such as the SLRPs
decorin, biglycan and lumican, or the BM-related
glycoprotein fibronectin. The combined analysis of
the glycan (glycomics) [65, 66] and the protein
(proteomics) forms the field of glycoproteomics.
Enzymatically deglycosylating a glycoprotein
allows for the separate analysis of the core protein
and of the glycan [67], but the aim of glycopro-
teomics is to combine both analyses, which makes
it a more challenging task: first, all proteins in the
sample are digested into peptides, and then, the
glycopeptides can be enriched followed by analysis
by LC-MS/MS. The obtained fragmentation spec-
trum can be very complex, because it contains
signals from the peptide backbone, the sugar
moiety and a combination of both (peptide frag-
ments with the sugar still attached) [68]. The
interpretation of such spectra requires significant
experience in interpretation, manual assignment
and evaluation. Consequently, high-throughput
analysis is precluded at present. Nevertheless,
glycoproteomics can be used to systematically
profile a given proteome [69].
Retention of lipoproteins in the vasculature
Further motivation for proteomic studies of the
vascular ECM arises from our lack of understand-
ing with regard to the ‘response-to-retention
hypothesis’ in early atherosclerosis [70]. Evidence
from biochemical and molecular biology studies
now supports the theory that ECM proteins, in
OH
Amino acid modifications overlooked = Non detectable peptide
Amino acid modifications included in search parameter = Detectable peptide
Collagen 1, α-1 chain (CO1A1)
72%
7%
Search with hydroxylation of Pro
Standard search
Hydroxyproline
GSPGADGPAGAPGTPGPQGIAGQR
GSPGADGPAGAPGTPGPQGIAGQR
Collagen 1, α-1 (CO1A1)
(a)
(b)
Fig. 2 Proline hydroxylation of collagens. Proline hydrox-
ylation (i.e. 4-hydroxyproline and 3-hydroxyproline) is a
common modification that confers stability to collagen
triple helices. (a) Inclusion of this variable modification in
the search parameters dramatically improves identifica-
tion and quantification of collagen peptides. The example
shown is a peptide spanning amino acid positions 935–
958 of human collagen 1, a-1 chain (CO1A1). (b) CO1A1
protein sequence coverage is also improved ~10-fold after
searching liquid chromatography–tandem mass spectrom-
etry data from human aortic specimen and including this
variable PTM. Pro, proline.
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particular vascular PGs, are involved in the reten-
tion of lipoproteins. However, it is still not clear
why some vessels are more susceptible to
atherosclerosis than others. This disparity is likely
to reflect inherent variations in vascular properties
and may include differences in ECM composition in
response to wall stress and shear flow that warrant
proteomic investigation.
Progression of atherosclerosis involves the forma-
tion of a lipid-rich necrotic core, and, as part of the
inherent repair process that ensues, a fibrous cap
forms over the core [71]. The ECM constituents of
this core along with the VSMC content have been
inextricably linked to the stability of the plaque
[72]. Collagen I accounts for ~60% of the total
protein in the fibrous cap, as corroborated by gene
expression data from atherosclerotic lesions in
mice [73]. In fact, the most over-expressed genes
associated with intimal hyperplasia encode ECM
proteins such as collagens I and III, in addition to
PGs. Given the tensile strength of fibrillar colla-
gens, it is perhaps unsurprising that their presence
is associated with stable plaques. By contrast,
vulnerable plaques are characterized by a thin cap
and a reduction in fibrillar collagen. Intimal PGs
are upregulated at sites of intimal thickening and
contribute to the development of atherosclerosis by
sequestering apoB-containing lipoproteins which
in turn stimulate the canonical chronic inflamma-
-S-S--S-S- COOHNH2
…HNQIRMIENGSLSFLPTL…
O-linked GAGs
N-linked oligosaccharides
Consensus sequence for N- glycosylation 
NxT/S
Biglycan
Biglycan Mimecan Galectin-1
1
2
3
Untreated
GAG removal
GAG and oligosaccharide removal
(a)
(b)
Fig. 3 Glycosylation of extracellular matrix (ECM) proteins. More than 90% of ECM proteins are glycosylated, which can
affect protein identification with antibodies. (a) Attachment of N-linked oligosaccharides to ECM proteins occurs at specific
consensus sequences. Biglycan is an example of a heavily glycosylated ECM protein. (b) Removal of glycosaminoglycans
(GAGs) and small oligosaccharides or removal of GAGs alone affects protein migration by gel electrophoresis. Biglycan
contains GAGs and oligosaccharides, and mimecan contains only N-linked oligosaccharides, whilst galectin-1 is a
nonglycosylated ECM protein. The aim of glycoproteomics is the identification of the protein core and the attached glycan.
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tory response in the vessel wall. Thus, we have
endeavoured to characterize the lipid content of
vulnerable and stable plaques [74] and identify
lipidomic signatures for CVD [75].
Given the vascular retention and accumulation of
apoB-containing lipoproteins, the importance of
remnants from triglyceride-rich lipoproteins has
recently been recognized. Evidence from Mendelian
randomized studies now suggests a primary role of
triglyceride-rich lipoproteins in CVD [76, 77]. The
lipolysis of triglycerides results in the conversion of
chylomicrons into chylomicron remnants and very
low-density lipoprotein (VLDL) particles into inter-
mediate-density lipoprotein (IDL) and low-density
lipoprotein (LDL). Lipoprotein lipase (attached to
the endothelium of blood capillaries) mediates this
process by hydrolysing the triglycerides carried in
chylomicrons and VLDL. Besides LDL, the lipolysis
of triglycerides yields triglyceride-depleted but
cholesterol-rich remnants (chylomicron remnants,
VLDL, and IDL in the nonfasting state, and VLDL
and IDL in the fasting state). The underlying
mechanism of remnant atherogenicity is thought
to be similar to that of LDL; that is, the triglyceride-
depleted and cholesterol-rich remnant particles are
trapped by the connective tissue in the arterial
wall. Chylomicrons and VLDL particles are too
large to penetrate the arterial wall. Remnants,
however, are small enough and may act in the
same atherogenic way as LDL. Of interest, Varbo
et al. provided evidence to suggest that remnants
are causally associated with inflammation and
ischaemic heart disease, whereas LDL was found
to have only a causal relationship with ischaemic
heart disease, indicating that the inflammatory
component in atherosclerosis is predominantly
driven by remnant particles [78]. Furthermore, it
has been suggested that nonfasting remnant
cholesterol levels may serve as a better biomarker
to predict CVD [79]. Ultimately, a comprehensive
analysis of molecular lipid species (lipidomics) and
apolipoproteins is required in CVD (see review by
Hinterwirth et al. [80]).
Other translational applications to vascular disorders
ECM proteins as biomarkers
Pursuing efforts to characterize ECM composition
has potential beyond the description of ECM
remodelling at a molecular level. Naba et al. [81]
have shown that comparing the extracellular pro-
teome of normal and cancerous tissues can lead to
biomarker identification. More importantly, de
Kleijn et al. [82] found that the level of the ECM
glycoprotein osteopontin in atherosclerotic plaques
was predictive for CVD events. As described above,
MMPs and TIMPs are currently believed to be the
major proteolytic mediators in the vessel wall.
Instead of circulating MMPs and TIMPs [83], the
proteolytic fragments of ECM proteins could be
used as measures of disease progression. This
possibility is particularly appealing because of the
release of these fragments into body fluids. For
instance, serological levels of elastin peptides and
the amino terminal of propeptide of collagen III
(PIIINP) have been correlated with abdominal
aneurysm progression [84]. PIIINP has also
received attention as a marker of atherosclerosis
[85]. Thus, it is likely that a proteomics approach
targeting the ECM will reveal new biomarker can-
didates with vascular specificity. ECM biomarkers
of clinical interest are summarized in Table 2.
ECM proteomics in drug discovery
Despite the number of diseases involving the
ECM, there are currently few drugs that specif-
ically target ECM components. The most promi-
nent examples of such drugs to date are those
that inhibit integrins, such as abciximab (to treat
thrombosis) and natalizumab (to treat multiple
sclerosis and Crohn’s disease) [86]. However,
there are numerous examples of other drug
classes that indirectly influence the ECM in a
favourable manner. For instance, it has been
postulated that angiotensin II antagonists also
act on the ECM by inhibiting TGFb [87]. Further-
more, in patients with Marfan’s syndrome, these
drugs were found to slow the rate of progression
of aortic-root dilatation. Unfortunately, these
concomitant effects on the ECM are largely non-
specific. Despite successful precedents, it has
been noted that ECM proteins are mainly over-
looked in drug discovery efforts [4].
Conclusions
During the progression of many vascular disor-
ders, the continuous pathological remodelling of
the ECM contributes to the manifestation of the
disease; for instance, the transition of a stable to
a vulnerable lesion in atherosclerosis [83], the
degradation and subsequent wall thinning in
abdominal aortic aneurysm [48] and neointimal
hyperplasia in vein graft disease [88] and varicose
veins [89]. The increasing performance of pro-
teomic platforms and the ability to provide large
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proteomic datasets, coupled with system biology
approaches, will ultimately facilitate the identifi-
cation of novel ‘druggable’ targets for and
biomarkers of CVD.
Conflict of interest statement
None.
Disclosures
ML has been awarded a British Heart Foundation
(BHF) PhD studentship. MM is a Senior Fellow of
the BHF (FS/13/2/29892) and member of the
network on ‘MicroRNA-based Therapeutic Strate-
gies in Vascular Disease’ funded by the Foundation
Leducq (MIRVAD; 13 CVD 02) and an excellence
Table 2 Extracellular matrix biomarkers in cardiovascular disease (CVD)
Biomarker Tissue Clinical context Main findings Reference
Biglycan Coronary artery Atherosclerosis Atherosclerotic segments have enriched deposits of
biglycan
[94]
Decorin Coronary artery Atherosclerosis Accumulation in intima of early atherosclerotic lesions [95]
Podocan Coronary artery Restenosis Reduced in restenotic coronary lesions [96]
Fibromodulin Coronary artery Atherosclerosis High expression associated with symptomatic plaques [97]
MMP-1 Serum Atherosclerosis Serum levels associated with plaque burden [98]
MMP-9 Plasma CVD Plasma concentration predictor of cardiovascular
mortality
[99]
MMP-10 Serum PAD Increased levels associated with clinical events [100]
MMP-12 Plasma Atherosclerosis,
CAD
Associated with severe atherosclerosis and increased
incidence of coronary events
[101]
TIMP-1 Plasma CVD Predictive of all-cause death, MI and cardiac mortality [102]
ADAMTS-1 Aorta and
coronary artery
Atherosclerosis Upregulated in the intima when plaque is present [43]
Cathepsin G Plasma Atherosclerosis Reduced in patients with atherosclerosis [103]
Cathepsin K Plasma CAD Elevated plasma levels in patients with CAD [104]
Collagen III Serum Acute MI High levels of collagen III fragments predict mortality [105]
Serum CAD Collagen III fragments predictive for atherosclerosis [85]
Collagen IV Coronary artery Atherosclerosis Aldehyde modifications in collagen IV increase risk of
clinical events
[106]
Osteopontin Carotid artery Atherosclerosis Predictive of vascular complications [82]
Periostin Cardiac valve Atherosclerotic
VHD
Upregulated in patients with atherosclerotic VHD [107]
Versican Plasma Atherosclerosis Degradation fragments elevated in patients with
atherosclerotic diseases
[108]
Fibronectin Abdominal aorta Atherosclerosis Enriched in atherosclerotic plaques [109]
Elastin Carotid artery Atherosclerosis Elevated levels of elastin fragments associated with
symptomatic carotid stenosis
[110]
Tenascin-C n/a Atherosclerosis SNP associated with atherosclerosis and CAD [111]
Matrix Gla
protein
n/a Atherosclerosis SNP influences calcification and is associated with
increased risk of MI
[112]
Galectin-3 Plasma CAD Increased levels are strong predictor of cardiovascular
death
[113]
CAD, coronary artery disease; CVD, cardiovascular disease; MI, myocardial infarction; PAD, peripheral artery disease;
SNP, single nucleotide polymorphism; VHD, valvular heart disease.
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